Literature DB >> 20942848

The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study.

A Tripodi, V Chantarangkul, C Guinet, M M Samama.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 20942848     DOI： 10.1111/j.1538-7836.2010.04106.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  30 in total

1.  Balancing efficacy and bleeding risk in the prevention of stroke due to atrial fibrillation with newer oral anticoagulants.

Authors:  M B Agarwal; Subhash Verma; Manoranjan Mahapatra; A K Tripathi; Abhay Bhave; Anand Deshpande; Amit Vora; Jamshed J Dalal; A B Shah; S Bichu
Journal:  Indian J Hematol Blood Transfus       Date:  2012-07-28       Impact factor: 0.900

Review 2.  Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review.

Authors:  Bethany T Samuelson; Adam Cuker; Deborah M Siegal; Mark Crowther; David A Garcia
Journal:  Chest       Date:  2016-09-13       Impact factor: 9.410

3.  Italian intersociety consensus on DOAC use in internal medicine.

Authors:  Domenico Prisco; Walter Ageno; Cecilia Becattini; Armando D'Angelo; Giovanni Davì; Raimondo De Cristofaro; Francesco Dentali; Giovanni Di Minno; Anna Falanga; Gualberto Gussoni; Luca Masotti; Gualtiero Palareti; Pasquale Pignatelli; Roberto M Santi; Francesca Santilli; Mauro Silingardi; Antonella Tufano; Francesco Violi
Journal:  Intern Emerg Med       Date:  2017-02-13       Impact factor: 3.397

Review 4.  Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations.

Authors:  Helen Mani; Alexander Kasper; Edelgard Lindhoff-Last
Journal:  J Thromb Thrombolysis       Date:  2013-08       Impact factor: 2.300

5.  Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL.

Authors:  Armando Tripodi; Walter Ageno; Marcello Ciaccio; Cristina Legnani; Giuseppe Lippi; Cesare Manotti; Rossella Marcucci; Marco Moia; Benedetto Morelli; Daniela Poli; Agostino Steffan; Sophie Testa
Journal:  Blood Transfus       Date:  2017-09-13       Impact factor: 3.443

Review 6.  Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication.

Authors:  Adam Cuker
Journal:  J Thromb Thrombolysis       Date:  2016-02       Impact factor: 2.300

Review 7.  Measurement and reversal of the direct oral anticoagulants.

Authors:  Bethany T Samuelson; Adam Cuker
Journal:  Blood Rev       Date:  2016-09-02       Impact factor: 8.250

8.  Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study.

Authors:  Meyer Michel Samama; Céline Guinet; Léna Le Flem; Emmanuel Ninin; Jean-Marc Debue
Journal:  J Thromb Thrombolysis       Date:  2013-02       Impact factor: 2.300

9.  Model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients.

Authors:  Hideki Yoshioka; Hiromi Sato; Hiroto Hatakeyama; Akihiro Hisaka
Journal:  Blood Adv       Date:  2018-05-22

Review 10.  Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.

Authors:  Adam Cuker; Deborah M Siegal; Mark A Crowther; David A Garcia
Journal:  J Am Coll Cardiol       Date:  2014-09-16       Impact factor: 24.094
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.